Rheumatologie

Portrait Dr. med. Lukas Wildi

Dr. med. Lukas Wildi

Chefarzt Rheumatologie
Facharzt für Rheumatologie
Facharzt für Innere Medizin

Aus- und Weiterbildung
2005Promotion zum Dr. med. der Universität Zürich: Pseudozystische Degeneration des lumbalen Ligamentum flavum
1995-2001Medizinstudium Universität Zürich
Berufliche Tätigkeit
11/2017Chefarzt Klinik für Rheumatologie, Kantonsspital Winterthur
10/2011-11/2017Klinik für Rheumatologie, Universitätsspital Zürich: Oberarzt
08/2009-08/2011Université de Montréal, Canada: Fellowship in Osteoarthritis
05/2008-06/2009Kantonsspital Schaffhausen, Innere Medizin A: Assistenzarzt
01/2006-01/2008Universitätsspital Zürich, Klinik für Rheumatologie, Rheumatologie A: Assistenzarzt
01/2005-12/2005Reha Rheinfelden, Rheumatologie B: Assistenzarzt
01/2003-12/2004FMI Spital Interlaken, Innere Medizin B: Assistenzarzt
01/2002-12/2002FMI Spital Interlaken, Allgemeine Chirurgie und Orthopädie: Assistenzarzt
Mitgliedschaften
  • AerzteGesellschaft des Kantons Zürich AGZ
  • Foederatio medicorum helveticorum FMH
  • Rheumaliga Schweiz, designiertes Vorstandsmitglied
  • Schweizerische Ärztegesellschaft für Manuelle Medizin
  • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
  • Schweizerischer Verband für Assistenz- und Oberärzte VSAO
  • Schweizerische Gesellschaft für Rheumatologie SGR, Vorstandsmitglied seit 08/2016, Delegationsleiter der Weiterbildungsstättenkommission
  • Zürcher Fachärztegesellschaft für Rheumatologie

Originalarbeiten

  1. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
    Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
    Ann Rheum Dis. 2017 Sep 22. pii: annrheumdis-2017-211544. doi: 10.1136/annrheumdis-2017-211544. [Epub ahead of print]
    PMID: 28939631
  2. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
    Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
    Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.
    PMID: 28724442
  3. MRI findings in the knee before and after running, with the focus on long distance running: Documentation of irreversible structural damage? A systematic review.
    Hoessly LM, Wildi LM. Am J Sports Med. 2017 Apr;45(5):1206-1217.
  4. Computer-based diagnostic expert systems in rheumatology: where do we stand in 2014?
    Alder H, Michel BA, Marx C, Tamborrini G, Langenegger T, Bruehlmann P, Steurer J, Wildi LM.
    Int J Rheumatol. 2014;2014:672714
  5. Relevant baseline characteristics for describing patients with knee osteoarthritis: results from a Delphi survey.
    Wildi LM, Hensel A, Wertli M, Michel BA, Steurer J.
    BMC Musculoskelet Disord. 2013 Dec 30;14:369
  6. Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons.
    Wildi LM, Martel-Pelletier J, Abram F, Moser T, Raynauld JP, Pelletier JP.
    Arthritis Care Res (Hoboken). 2013 May;65(5):686-94
  7. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
    Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP.
    Ann Rheum Dis. 2011 Jun;70(6):982-9
  8. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.
    Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP.
    Ann Rheum Dis. 2010 Dec;69(12):2118-24
  9. Pseudocystic degeneration of the lumbar ligamentum flavum: a little known entity.
    Wildi LM, Kurrer MO, Benini A, Weishaupt D, Michel BA, Brühlmann P..
    J Spinal Disord Tech. 2004 Oct;17(5):395-400
  10. Cross-cultural adaptation of the German version of the spinal stenosis measure.
    Wertli MM, Steurer J, Wildi LM, Held U.
    Eur Spine J. 2014 Jun;23(6):1309-19
  11. Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort.
    Raynauld JP, Wildi LM, Abram F, Moser T, Pelletier JP, Martel-Pelletier J. J. Biomedical Science and Engineering, 2013. 6: p. 337-45
  12. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate.
    Raynauld JP, Martel-Pelletier J, Dorais M, Haraoui B, Choquette D, Abram F, Beaulieu A, Bessette L, Morin F, Wildi LM, Pelletier JP.
    Cartilage. 2013 Jul;4(3):219-26
  13. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.
    Raynauld JP, Martel-Pelletier J, Haraoui B, Choquette D, Dorais M, Wildi LM, Abram F, Pelletier JP.
    Ann Rheum Dis. 2011 Aug;70(8):1382-8

Narrative Reviews

  1. Osteoarthritis : What internists should know.
    Wildi L
    Internist (Berl). 2015 May;56(5):527-43
  2. Pharmacological therapy of arthrosis.
    Wildi LM
    Z Rheumatol. 2013 Nov;72(9):885-94
  3. Future therapeutics for osteoarthritis.
    Martel-Pelletier J, Wildi LM, Pelletier JP.
    Bone. 2012 Aug;51(2):297-311

Case Reports

  1. Reversible male infertility under treatment with an anti-TNFα agent: a case report.
    Wildi LM, Haraoui B.
    Ann Rheum Dis. 2012 Mar;71(3):473-4

Buchkapitel

  1. “Biomarkers in Osteoarthritis” in “Understanding Osteoarthritis from Bench to Bedside”
    Wildi LM, Tamborrini G
    Editors Martel-Pelletier J. and Pelletier J.P. Research Signpost, Kerala, India
  • Curriculum vitae
    Aus- und Weiterbildung
    2005Promotion zum Dr. med. der Universität Zürich: Pseudozystische Degeneration des lumbalen Ligamentum flavum
    1995-2001Medizinstudium Universität Zürich
    Berufliche Tätigkeit
    11/2017Chefarzt Klinik für Rheumatologie, Kantonsspital Winterthur
    10/2011-11/2017Klinik für Rheumatologie, Universitätsspital Zürich: Oberarzt
    08/2009-08/2011Université de Montréal, Canada: Fellowship in Osteoarthritis
    05/2008-06/2009Kantonsspital Schaffhausen, Innere Medizin A: Assistenzarzt
    01/2006-01/2008Universitätsspital Zürich, Klinik für Rheumatologie, Rheumatologie A: Assistenzarzt
    01/2005-12/2005Reha Rheinfelden, Rheumatologie B: Assistenzarzt
    01/2003-12/2004FMI Spital Interlaken, Innere Medizin B: Assistenzarzt
    01/2002-12/2002FMI Spital Interlaken, Allgemeine Chirurgie und Orthopädie: Assistenzarzt
    Mitgliedschaften
    • AerzteGesellschaft des Kantons Zürich AGZ
    • Foederatio medicorum helveticorum FMH
    • Rheumaliga Schweiz, designiertes Vorstandsmitglied
    • Schweizerische Ärztegesellschaft für Manuelle Medizin
    • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
    • Schweizerischer Verband für Assistenz- und Oberärzte VSAO
    • Schweizerische Gesellschaft für Rheumatologie SGR, Vorstandsmitglied seit 08/2016, Delegationsleiter der Weiterbildungsstättenkommission
    • Zürcher Fachärztegesellschaft für Rheumatologie
  • Publikationen

    Originalarbeiten

    1. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
      Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
      Ann Rheum Dis. 2017 Sep 22. pii: annrheumdis-2017-211544. doi: 10.1136/annrheumdis-2017-211544. [Epub ahead of print]
      PMID: 28939631
    2. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
      Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
      Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.
      PMID: 28724442
    3. MRI findings in the knee before and after running, with the focus on long distance running: Documentation of irreversible structural damage? A systematic review.
      Hoessly LM, Wildi LM. Am J Sports Med. 2017 Apr;45(5):1206-1217.
    4. Computer-based diagnostic expert systems in rheumatology: where do we stand in 2014?
      Alder H, Michel BA, Marx C, Tamborrini G, Langenegger T, Bruehlmann P, Steurer J, Wildi LM.
      Int J Rheumatol. 2014;2014:672714
    5. Relevant baseline characteristics for describing patients with knee osteoarthritis: results from a Delphi survey.
      Wildi LM, Hensel A, Wertli M, Michel BA, Steurer J.
      BMC Musculoskelet Disord. 2013 Dec 30;14:369
    6. Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons.
      Wildi LM, Martel-Pelletier J, Abram F, Moser T, Raynauld JP, Pelletier JP.
      Arthritis Care Res (Hoboken). 2013 May;65(5):686-94
    7. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
      Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP.
      Ann Rheum Dis. 2011 Jun;70(6):982-9
    8. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.
      Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP.
      Ann Rheum Dis. 2010 Dec;69(12):2118-24
    9. Pseudocystic degeneration of the lumbar ligamentum flavum: a little known entity.
      Wildi LM, Kurrer MO, Benini A, Weishaupt D, Michel BA, Brühlmann P..
      J Spinal Disord Tech. 2004 Oct;17(5):395-400
    10. Cross-cultural adaptation of the German version of the spinal stenosis measure.
      Wertli MM, Steurer J, Wildi LM, Held U.
      Eur Spine J. 2014 Jun;23(6):1309-19
    11. Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort.
      Raynauld JP, Wildi LM, Abram F, Moser T, Pelletier JP, Martel-Pelletier J. J. Biomedical Science and Engineering, 2013. 6: p. 337-45
    12. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate.
      Raynauld JP, Martel-Pelletier J, Dorais M, Haraoui B, Choquette D, Abram F, Beaulieu A, Bessette L, Morin F, Wildi LM, Pelletier JP.
      Cartilage. 2013 Jul;4(3):219-26
    13. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.
      Raynauld JP, Martel-Pelletier J, Haraoui B, Choquette D, Dorais M, Wildi LM, Abram F, Pelletier JP.
      Ann Rheum Dis. 2011 Aug;70(8):1382-8

    Narrative Reviews

    1. Osteoarthritis : What internists should know.
      Wildi L
      Internist (Berl). 2015 May;56(5):527-43
    2. Pharmacological therapy of arthrosis.
      Wildi LM
      Z Rheumatol. 2013 Nov;72(9):885-94
    3. Future therapeutics for osteoarthritis.
      Martel-Pelletier J, Wildi LM, Pelletier JP.
      Bone. 2012 Aug;51(2):297-311

    Case Reports

    1. Reversible male infertility under treatment with an anti-TNFα agent: a case report.
      Wildi LM, Haraoui B.
      Ann Rheum Dis. 2012 Mar;71(3):473-4

    Buchkapitel

    1. “Biomarkers in Osteoarthritis” in “Understanding Osteoarthritis from Bench to Bedside”
      Wildi LM, Tamborrini G
      Editors Martel-Pelletier J. and Pelletier J.P. Research Signpost, Kerala, India